PE20180466A1 - Concentrado que contiene alprostadil - Google Patents
Concentrado que contiene alprostadilInfo
- Publication number
- PE20180466A1 PE20180466A1 PE2018000129A PE2018000129A PE20180466A1 PE 20180466 A1 PE20180466 A1 PE 20180466A1 PE 2018000129 A PE2018000129 A PE 2018000129A PE 2018000129 A PE2018000129 A PE 2018000129A PE 20180466 A1 PE20180466 A1 PE 20180466A1
- Authority
- PE
- Peru
- Prior art keywords
- water
- acid
- active principle
- mixture
- concentrate containing
- Prior art date
Links
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000711 alprostadil Drugs 0.000 title abstract 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title abstract 3
- 239000012141 concentrate Substances 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 238000001802 infusion Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000011877 solvent mixture Substances 0.000 abstract 2
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion se refiere a una composicion farmaceutica liquida en forma de un concentrado para la preparacion de una solucion para infusion, que contiene alprostadil (prostaglandina E1) como principio activo, disuelto en una mezcla de disolventes de al menos un disolvente organico farmaceuticamente aceptable y agua, y se caracteriza por que la proporcion de agua total en la mezcla de disolventes se encuentra en el intervalo del 8 al 85 % en peso de agua, referido a la cantidad total de la mezcla de disolventes, y porque al menos un acido o una sustancia que actua de acido o de donante de protones esta contenida como estabilizador para el principio activo. Esta composicion es util en el tratamiento de la enfermedad arterial oclusiva periferica (EAOP), especialmente mediante infusion intravenosa
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ATA50666/2015A AT518009A1 (de) | 2015-07-27 | 2015-07-27 | Konzentrat enthaltend Alprostadil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180466A1 true PE20180466A1 (es) | 2018-03-06 |
Family
ID=56852017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000129A PE20180466A1 (es) | 2015-07-27 | 2016-07-25 | Concentrado que contiene alprostadil |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3328358B1 (es) |
| AR (1) | AR105504A1 (es) |
| AT (1) | AT518009A1 (es) |
| BR (1) | BR112018001637A2 (es) |
| CO (1) | CO2018000525A2 (es) |
| MX (1) | MX2018001042A (es) |
| PE (1) | PE20180466A1 (es) |
| WO (1) | WO2017015692A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0669966B2 (ja) * | 1989-07-05 | 1994-09-07 | 株式会社ミドリ十字 | 血管造影補助剤 |
| ES2142409T3 (es) * | 1993-10-27 | 2000-04-16 | Upjohn Co | Prostaglandina e 1 estabilizada. |
| DE4342232A1 (de) * | 1993-12-10 | 1995-06-14 | Hexal Pharma Gmbh | Feste Zubereitung für therapeutische Zwecke mit einem Gehalt an Prostaglandin E1 |
| CN102048687A (zh) * | 2009-11-06 | 2011-05-11 | 华北制药集团制剂有限公司 | 一种前列地尔注射液的制备方法 |
| CN103110579B (zh) * | 2013-02-20 | 2014-12-10 | 北京德立福瑞医药科技有限公司 | 前列地尔注射剂 |
-
2015
- 2015-07-27 AT ATA50666/2015A patent/AT518009A1/de not_active Application Discontinuation
-
2016
- 2016-07-25 PE PE2018000129A patent/PE20180466A1/es unknown
- 2016-07-25 EP EP16759666.7A patent/EP3328358B1/de active Active
- 2016-07-25 WO PCT/AT2016/060020 patent/WO2017015692A1/de not_active Ceased
- 2016-07-25 MX MX2018001042A patent/MX2018001042A/es unknown
- 2016-07-25 BR BR112018001637A patent/BR112018001637A2/pt not_active IP Right Cessation
- 2016-07-27 AR ARP160102285A patent/AR105504A1/es not_active Application Discontinuation
-
2018
- 2018-01-19 CO CONC2018/0000525A patent/CO2018000525A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3328358A1 (de) | 2018-06-06 |
| WO2017015692A1 (de) | 2017-02-02 |
| AT518009A1 (de) | 2017-06-15 |
| MX2018001042A (es) | 2018-06-07 |
| BR112018001637A2 (pt) | 2018-09-18 |
| AR105504A1 (es) | 2017-10-11 |
| CO2018000525A2 (es) | 2018-04-10 |
| EP3328358B1 (de) | 2022-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015025172A2 (pt) | composição farmacêutica | |
| BR112017017888A2 (pt) | derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes | |
| AR112480A1 (es) | Composiciones de glp-1 y sus usos | |
| CO7111300A2 (es) | Formulación de anticuerpos | |
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| MX2018003096A (es) | Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma. | |
| PE20141297A1 (es) | Formulaciones peptidicas robustas de liberacion controlada | |
| NI201300127A (es) | Formulaciones peptídicas de liberación controlada. | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| BR112014010590A2 (pt) | 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose | |
| ECSP14013200A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| PE20150226A1 (es) | Agentes terapeuticos para administracion subcutanea optimizados | |
| PE20150345A1 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo | |
| BR112015022290A2 (pt) | derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120 | |
| PE20180466A1 (es) | Concentrado que contiene alprostadil | |
| CO2018000526A2 (es) | Concentrado que contiene alprostadil | |
| AR090959A1 (es) | Analogos de hexadepsipeptidos como compuestos anticancerigenos | |
| MX2019011386A (es) | Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion. | |
| MX369244B (es) | Solucion alcoholica estable de alprostadilo. | |
| CL2018003269A1 (es) | Ácidos carboxílicos para aplicación en la primera infancia. | |
| MX2017007567A (es) | Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales. | |
| WO2013114418A8 (en) | Transdermal administration of prostaglandin e1 for the treatment of ocular ischemia | |
| AR074470A1 (es) | Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes |